American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 349-350 , April 2008

A new model of ovarian carcinogenesis may influence early detection strategies

Received 31 December 2007 ,Accepted 10 January 2008.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  3. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst. 2000;92:699–708
  4. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529
  5. Meinhold-Heerlein I, Bauerschlag D, Zhou Y, et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res. 2007;13(2 Pt 1):458–466
  6. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: A pilot randomised controlled trial. Lancet. 1999;353:1207–1210
  7. Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement. 2007;http://www.wcn.org/ov_cancer_cons.htmlAccessed December 2007

PII: S0002-9378(08)00019-7

doi: 10.1016/j.ajog.2008.01.004

American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 349-350 , April 2008

Article Tools